Natural health product · DIN 02103109
Eltor
No: licence discontinued
The licence holder discontinued the product licence.
Licence status Discontinued; licensed December 17, 2009; licence last revised February 7, 2019.
- DIN
- 02103109
- Licence holder
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Dosage form
- Caplet
- Route
- Oral
- Licensing route
- Transitional DIN
- First licensed
- December 17, 2009
- Licence last revised
- February 7, 2019
Medicinal ingredients
Per dosage unit, as licensed.
| Ingredient | Amount | Source and potency |
|---|---|---|
| (1S, 2S)-2-Methylamino-1-phenylpropan-1-ol hydrochloride | 120 mg | Synthetic |
What it is licensed for
The licence’s own wording. Directions, doses, cautions and warnings are on the official record and the label.
- ELTOR® is indicated for conditions of acute coryza, sinusitis, and vasomotor or allergic rhinitis, by providing temporary nasal and sinus decongestion. It may also be used as an adjunct to antibiotics, antihistamines, analgesics and antitussives in the treatment of the above conditions. Decongestant - 12 hour relief of sinus and nasal congestion due to colds and allergies.
Non-medicinal ingredients
Sucrose; Silicon dioxide; Methylcellulose; Magnesium Stearate; Hypromellose